Sosei Heptares to regain rights to muscarinic agonist programmes

pharmafile | January 5, 2021 | News story | Manufacturing and Production Sosei Heptares 

Biopharmaceutical group Sosei Heptares has announced it is to regain the worldwide rights to its muscarinic agonist programmes, after they were licensed to Allergan in April 2016, and Allergan was subsequently acquired by AbbVie in May 2020.

The decision to return worldwide rights was based on business decisions regarding AbbVie’s pipeline strategy, rather than any efficacy, safety or other data related to the collaboration programmes.

As a result of this process, AbbVie has notified Sosei Heptares that it will be returning all assets in development under the programme, together with all associated intellectual property licensed by Sosei Heptares to Allergan, and all clinical and preclinical data generated under the partnership.

The biopharmaceutical group will now conduct a full internal review to determine a strategy for the further development and re-partnering of the programme, the outcome of which is expected to be reported around February of this year.

Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, said: “We are delighted to regain rights to this portfolio of novel subtype-selective muscarinic receptor agonists (M4, M1 and dual M1/M4 agonists), including several clinical and preclinical candidates with substantial data associated.

“We enjoyed a productive relationship with Allergan over the course of our muscarinic agonist collaboration and continue to work positively with AbbVie on a new programme in inflammatory diseases that we announced in June last year.

“The considerable progress that we made together with Allergan has reinforced our view in the potential of this approach to create important new products that treat severe and debilitating symptoms of Alzheimer’s disease, schizophrenia and other neurological diseases. We are also encouraged by the growing industry interest and validation of this novel approach to treating these diseases.”

Darcy Jimenez

Related Content


Neurocrine Biosciences begins phase 1 study assessing NBI-1117570 in healthy adults

Sosei Heptares has announced that its partner, Neurocrine Biosciences, has initiated its phase 1 first-in-human …


Sosei Heptares and Cancer Research UK announce first patient dosed in phase 1/2a trial

Sosei Heptares and Cancer Research UK have announced that the first patient has been dosed …


Sosei Heptares announces first subject dosed in phase 1 trial for schizophrenia therapy

Sosei Heptares has announced that it has dosed its first patient in its phase 1 …

Latest content